Upgrade to SI Premium - Free Trial

AstraZeneca (AZN) Announces Imfinzi Granted Priority Review

October 17, 2017 6:19 AM
AstraZeneca (NYSE: AZN) and MedImmune, its global biologics research and development arm, today announced that the US Food and Drug ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Management Comments

Next Articles